Feline lymphocyte populations from blood, spleen, lymph node, thymus and bone marrow were examined for the following markers: rosette formation with guinea pig erythrocytes (GPE-T cells); surface feline thymocyte antigen (T cells); surface immunoglobulin (B cells); cytoplasmic immunoglobulin (preB cells, plasma cells); receptors for the Fc portion of IgG (FcyR-positive T and B cells), and the third component of complement (CR-positive cells – primarily B cells). The blastogenic responses of feline lymphocytes from peripheral blood, spleen, lymph node (LN), thymus and marrow were investigated using the following mitogens: Escherichia coli lipopolysaccharide (LPS), dextran sulfate (DxS), concanavalin A (conA), phytohemagglutinin (PHA) and pokeweed mitogen (PWM). Feline T lymphocytes identified by rosette formation with GPE and surface thymocyte antigen were present in thymus, spleen, LN, blood and, rarely, in marrow. T cell subsets, but not B cell subsets, were differentiated according to mitogen activation. Cells responding to PHA were immature, nonrecirculating cells, which were most strongly activated in thymus [stimulation index (SI = 12)], lymph node(SI = 11) and spleen (SI = 6). PWM-responsive cells were relatively mature, recirculating lymphocytes of widespread distribution and blastogenesis was greater in spleen (SI = 36) and LN (SI = 29), followed by thymus (SI = 23) and blood (SI = 15). Con A was a potent mitogen for cells of spleen (SI = 113), blood (SI = 80) and LN (SI = 77), but not thymus (SI = 7), suggesting that the con-A-inducible cell was a mature, recirculating, postthymic cell. Optimal mitogenic response to the B cell mitogen, LPS, was dependent upon increased cell concentrations (3 × 105 versus 1 × 105 per microtiter well) and increased incubation time (5 days versus 3 days). Surface IgG- and IgM-bearing lymphocytes and CR-bearing cells from spleen and blood were stimulated preferentially. DxS was moderately mitogenic for CR-bearing lymphocytes in spleen (SI=4), LN (SI=3) and blood (SI = 3), but not marrow (SI= 1).

This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.